Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.48 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 3/20 | 0.45 |
| ▸ | CA2 | P00918 | 3/20 | 0.45 |
| ▸ | MMP1 | P03956 | 1/20 | 0.45 |
| ▸ | MMP2 | P08253 | 1/20 | 0.45 |
| ▸ | MMP9 | P14780 | 1/20 | 0.45 |
| ▸ | MMP8 | P22894 | 1/20 | 0.45 |
| ▸ | MMP13 | P45452 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 2/20 | 0.44 |
| ▸ | CA3 | P07451 | 2/20 | 0.44 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | CA6 | P23280 | 2/20 | 0.44 |
| ▸ | CA5A | P35218 | 2/20 | 0.44 |
| ▸ | CA7 | P43166 | 2/20 | 0.44 |
| ▸ | CA9 | Q16790 | 2/20 | 0.44 |
| ▸ | CA13 | Q8N1Q1 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL368914 | 0.84 | F2 (0.49) | ALDH1A1HSP90AA1CA1CA2MMP1 | |
| SCHEMBL10730288 | 0.79 | ALDH1A1 (0.44) | ALDH1A1HSP90AA1HSD11B1CA1CA2 | |
| SCHEMBL30865768 | 0.79 | CA1 (0.53) | ALDH1A1HSP90AA1CA1CA2MMP1 | |
| SCHEMBL5968990 | 0.78 | ALDH1A1 (0.49) | ALDH1A1HSP90AA1TDP1KMT2AMEN1 | |
| SCHEMBL875775 | 0.77 | F2 (0.45) | ALDH1A1HSP90AA1HSD11B1CA1CA2 | |
| SCHEMBL2540780 | 0.77 | PKM (0.65) | ALDH1A1HSD11B1CYP1A2CYP2C19KMT2A | |
| SCHEMBL1759088 | 0.77 | TSHR (0.49) | ALDH1A1HSP90AA1HSD11B1CA1CA2 | |
| SCHEMBL8402357 | 0.76 | CA1 (0.50) | ALDH1A1HSP90AA1CA1CA2MMP1 | |
| SCHEMBL19126863 | 0.76 | CA1 (0.50) | ALDH1A1HSP90AA1HSD11B1CA1CA2 | |
| SCHEMBL4456811 | 0.76 | CA1 (0.50) | ALDH1A1HSP90AA1CA1CA2MMP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY LTD. (AU) | 2008-10-16 | — | — | US | disclosed |
| EP-1879564-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | Astrum Therapeutics Pty, Ltd. (AU) | 2008-01-23 | — | — | EP | disclosed |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | ASTRUM THERAPEUTICS PTY LTD (AU) | 2006-11-09 | — | — | US | disclosed |
| WO-2006110477-A2 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | ASTRUM THERAPEUTICS PTY. LTD. (AU) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255091-A1 | COMPOUNDS TO TREAT AMYLOIDOSIS AND PREVENT DEATH OF BETA-CELLS IN TYPE 2 DIABETES MELLITUS | IAPP, BCL2, AMY2A | ALDH1A1 2700/4885HSP90AA1 710/4885HSD11B1 2158/4885 |
| US-20060252819-A1 | Compounds to treat amyloidosis and prevent death of beta-cells in type 2 diabetes mellitus | IAPP, BCL2, AMY2A | ALDH1A1 2700/4885HSP90AA1 710/4885HSD11B1 2158/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.